EDVA Patent Case Against Virginia Companies Transferred to New York

Typically, a plaintiff can feel confident that a patent infringement claim filed in the Eastern District of Virginia against Virginia-based defendants will not be transferred – but that’s not always the case, as shown by Judge Hudson’s recent decision, found here, to transfer venue in Augme Tech’s., Inc. v. Gannett Co., Inc., et al., Case No. 3:11CV282, 2011 U.S. Dist. LEXIS 81605 (E.D.Va. July 26, 2011) (Hudson, J.).

Augme Tech's is an example of the increasingly common tactic of filing a “mass patent” case in which a plaintiff asserts infringement of the same patents against multiple independent defendants who are acting separately. 

Despite some case law to the contrary, most EDVA judges are reluctant to sever individual defendants in such cases because of the risk of inconsistent claim constructions and verdicts. Thus, a plaintiff can draw out-of-state defendants into the EDVA’s faster docket by including Virginia defendants in the suit and using the presence of the Virginia defendants to defeat a motion to transfer venue.

That strategy did not work for Augme, which sued two defendants, Gannett and LucidMedia Networks, which were based in Virginia, and a third defendant, AOL, which has a substantial presence in Virginia, for infringement of patents for adding function to Internet web pages. Regardless of the Virginia defendants, Judge Hudson found that other factors required transfer of venue to New York.

The key considerations cited by the Court were:

  • Virginia was not Augme’s home forum, and so Augme’s choice of forum was not entitled to any deference;
  • Augme and AOL had been litigating a closely related action involving the same family of patents in the Southern District of New York for four years – which gave a strong appearance of forum-shopping to Augme’s Virginia action;
  • New York was Augme’s (and AOL’s) home forum, and Augme was actively litigating claims there

In ordering transfer, Judge Hudson relied primarily on the interest of justice, particularly the risk of inconsistent judgments and the New York Court’s familiarity with the technology and the patent family at issue.

In the end, Augme will be forced to litigate in both forums, as Judge Hudson agreed to sever LucidMedia’s cross-claim for infringement of a separate patent and retain venue over that dispute.

Tobacco trademark ghetto challenged

As reported recently by Virginia Lawyers Weekly, four small cigarette manufacturers have filed suit in the United States District Court for the Eastern District of Virginia, challenging a FDA regulation adopted on March 19, 2010, regarding tobacco product brand names.  According to the plaintiffs, the regulation would send their valuable IP rights up in smoke.

In Renegade Tobacco Company, et al. v. FDA, E.D. Va. case no. 3:10-cv-265, the companies challenge 21 C.F.R. § 1140.16(a), which provides that tobacco product manufacturers:

shall not use a trade or brand name of a nontobacco product as the trade or brand name for a cigarette or smokeless tobacco product, except for a tobacco product whose trade or brand name was on both a tobacco product and a nontobacco product that were sole in the United States on January 1, 1995.

The Complaint alleges that the regulation applies even to wholly unrelated manufacturers and products, regardless of whether there is any likelihood of confusion by consumers, regardless of who first used or registered the name with the USPTO, and regardless of whether the products are sold in the same geographic markets.

For example, the Complaint alleges that Renegade, one of the plaintiff manufacturers, would be forced to stop using its “Tucson” cigarette trademark because of Hyundai’s SUV of the same name.  By contrast, names and marks like “Marlboro,” “Newport,” “Camel,” “Doral,” and “Winston” would survive under the 1995 grandfather clause.

The Complaint further alleges that the regulation invites brand/product name squatting and extortion, much like the problems with domain names that led to enactment the Anticybersquatting Consumer Protection Act, 15 U.S.C. § 1125(d).

The claims in the Complaint are that the regulation violates the First Amendment’s free speech provision and the Equal Protection and Due Process Clauses of the Fifth Amendment, and that the regulation is ultra vires.

Although constitutional arguments may attract most of the legal ink, the case presents the fascinating IP situation of the federal government establishing rules that effectively disadvantage categories of trademarks and trade names for disfavored businesses.

The regulation is scheduled to take effect on June 22, 2010, but the FDA asserts that it is under review and that the agency has agreed not to enforce the regulation until that review is complete (and therefore that the case seeks relief not yet necessary and premature adjudication of constitutional issues).  For more information, see the memorandum in support of and opposition to the plaintiffs’ motion for a preliminary injunction, upon which a hearing has been set for May 27, 2010, before Judge Henry E. Hudson of the Eastern District’s Richmond division.

Much ado about too many words

            Hopefully you have already gotten a gift for that special IP litigant in your life this year.  If you’re thinking ahead to a 2010 wish list and have a preliminary injunction in mind, you may have noticed last month’s opinion by U.S. District Judge Henry E. Hudson in PRE Holding, Inc. v. Monaghan Medical Corp., no. 3:09CV458, 2009 U.S. Dist. LEXIS 107222 (E.D. Va. Nov. 17, 2009) (page citations to this opinion are to the version freely available from PACER/ECF).

            Other IP web news sources have questioned whether this opinion raises the bar for a preliminary injunction for patent litigants and whether it is consistent with case law from the U.S. Court of Appeals for the Federal Circuit.  (Federal Circuit law governs the issuance of injunctive relief under 35 U.S.C § 283 because the question “involves substantive matters unique to patent law.”  E.g., Hybritech, Inc. v. Abbott Labs, 849 F.2d 1446, 1451 n.12 (Fed. Cir. 1988).  “[P]urely procedural questions . . . are controlled by the law of the appropriate regional circuit.”  Id.

            In the post below, I conclude that debate over the PRE Holding opinion reflects the difficulties with the preliminary injunction standard and the hazards of not being concise, and that the PRE Holding opinion does not represent a change in the law.

 

            Discussion of federal preliminary injunction law must now begin with two recent United States Supreme Court cases. 

             In Munaf v. Geren, 553 U.S. ___, 128 S.Ct. 2207 (2008), the Supreme Court vacated and remanded decisions on two habeas petitions by detainees, who sought, inter alia, preliminary injunctions to prevent transfer to Iraqi custody.  Regarding the preliminary injunction, the Court “beg[a]n with the basics”:  “A preliminary injunction is an ‘extraordinary and drastic remedy,’” that “is never awarded as of right.  Rather, a party seeking a preliminary injunction must demonstrate, among other things, ‘a likelihood of success on the merits.’”  Id. at 2219.  The Court found fault with the lower court’s failure to apply that standard.  Id. (quoting Omar v. Harvey, 416 F. Supp. 2d 19, 23-24 (D.C. 2006)).  Although the D.C. district court had not relied on the case specifically, it had applied a preliminary injunction test indistinguishable from that adopted by the Fourth Circuit in Blackwelder Furniture Co. v. Seilig Manufacturing Co., 550 F.2d 189 (4th Cir. 1977).  See, e.g., Omar, 416 F. Supp. 2d at 22, 29.

             For more on Blackwelder and the change in the law, along with a discussion of the law in Virginia state court, see this article by Brad Davenport and yours truly in the Spring 2009 Virginia State Bar’s Litigation section news, as well as this brief update in the Fall 2009 issue, noting that the Fourth Circuit later officially put Blackwelder to rest in The Real Truth About Obama, Inc. v. Federal Election Commission et al., 575 F.3d 342, 346 (4th Cir. 2009).

            In Winter v. Natural Resources Defense Council, Inc., 129 S.Ct. 365 (2008), the Supreme Court reversed a Ninth Circuit decision affirming a district court’s grant of a preliminary injunction imposing restrictions on the Navy’s use of active sonar to prevent harm to sea animals.  Citing Munaf and other cases, the Court explained that “A plaintiff seeking a preliminary injunction must establish that he is likely to succeed on the merits, that he is likely to suffer irreparable harm in the absence of preliminary relief, that the balance of equities tips in his favor, and that an injunction is in the public interest.”  Id. at 374 (emphasis added, citations omitted).  As they had done in Munaf, the lower courts in Winter employed a flexible analysis in which a strong showing on one factor allowed a much weaker showing on another – the twist was that the lower courts had concluded there was a strong likelihood of success on the merits, making the “‘possibility’ of irreparable harm” sufficient.  Id. at 375.  The Supreme Court reiterated its “extraordinary remedy” language from Munaf and stated that its “frequently reiterated standard requires plaintiffs seeking preliminary relief to demonstrate that irreparable injury is likely in the absence of an injunction.”  Id. at 375-76.

            With that necessary background, let’s turn to the opinion in PRE Holding.

            After quoting the Winter standard, the Court repeated several points “accentuated” by the U.S. Supreme Court – namely, “that a plaintiff seeking preliminary relief must demonstrate ‘that irreparable harm is likely in the absence of an injunction’” and that “‘injunctive relief [is] an extraordinary remedy that may only be awarded upon a clear showing that the plaintiff is entitled to such relief.’”  PRE Holding at 2 (quoting Winter). 

            The Court then noted that the Federal Circuit had used “likely” in describing what a patent plaintiff need prove for a preliminary injunction prior to Winter, citing Sanofi-Synthelabo v. Apotex, Inc., 470 F.3d 1368, 1374 (Fed. Cir. 2006).  And it quoted Altana Pharma AG v. Teva Pharms. USA, Inc., 566 F.3d 999, 1006 (Fed. Cir. 2009), for the proposition that “if the accused infringer 'raises a substantial question concerning validity, enforceability, or infringement (i.e., asserts a defense that [the movant] cannot show 'lacks substantial merit') that preliminary injunction should not issue.’”  PRE Holding at 2-3.

             After discussing the patents at issue, the Court concluded as follows:  “While the evidence appears to tilt in Plaintiffs' favor, the Court must conclude at this preliminary stage that the evidence, when collectively viewed, still raises a substantial question as to whether the exhalation pathways are sufficiently similar structurally to warrant a finding of infringement….  ‘[b]ecause a preliminary injunction affords, on a temporary basis, the relief that can be granted permanently after trial, the party seeking the preliminary injunction must demonstrate by 'a clear showing' that, among other things, it is likely to succeed on the merits at trial.’  Plaintiffs' evidence fails to meet this standard at this stage.”  Id. at 8 (quoting Real Truth About Obama) (citations omitted).

            What seems to have stirred debate is that the Court quoted Fourth Circuit case law and repeated Winter’s “clear showing” language, which some label as dictum, rather than stating that there needed to be a “reasonable likelihood” of success on the merits (language used in some pre-Winter Federal Circuit cases).

             The first problem is one of wording and clarity.  The standard for preliminary injunctions already contains vast amounts of wiggle room, both because it asks a judge to weigh the “likelihood of success” in litigation and because “the patentee's entitlement to such an injunction is a matter largely within the discretion of the trial court.”  Titan Tire Corp. v. Case New Holland, Inc., 566 F.3d 1372, 1375 (Fed. Cir. 2009). (Thus, a “deferential standard of review” applies, requiring “a showing that ‘the court made a clear error of judgment in weighing relevant factors or exercised its discretion based upon an error of law or clearly erroneous factual findings.’”  Id.

            When you already have a “likelihood” standard, on which discretionary decisions are made, adding additional language – e.g., a “reasonable likelihood,” or a “clear showing” – serves more to obfuscate than anything else.  Making matters less clear by adding words is a problem lawyers routinely confront, and courts are not immune. 

            Indeed, the Federal Circuit itself recently expressed puzzlement at the effect of its own cases’ language.  See Titan Tire Corp. v. Case New Holland, Inc., 566 F.3d 1372, 1376 (Fed. Cir. 2009) (“It is not clear whether the addition of ‘reasonable’ adds anything substantive to the test”).  The Federal Circuit further noted that some commentators have concluded the answer is no.  See id. at 1376 n.2 (quoting the Wright & Miller treatise’s conclusion that, despite the “bewildering variety of formulations of the need for showing some likelihood of success,” “the verbal differences do not seem to reflect substantive disagreement”).

             Moreover, concluding that PRE Holding raises the bar (assuming that one could discern where the bar was before and that it is different now), seems to ignore that the Court was plainly applying its view of both Winter and Federal Circuit law. 

            In PRE Holding, the Court applied the four-factor test from Winter.  On the first factor (“likelihood of success on the merits”), the Court concluded “that the evidence, when collectively viewed, still raises a substantial question as to whether the exhalation pathways are sufficiently similar structurally to warrant a finding of infringement.”  PRE Holding at 8.  That “substantial question” language echoes the Federal Circuit in Altana Pharma AG, 566 F.3d at 1006, which the Court had quoted previously in its opinion. 

            The Federal Circuit has explained what the “substantial question” language means, see Titan Tire 566 F.3d at 1377-79, but as it has stated, the bottom line is that Winter governs in patent infringement cases too.  See id. at 1380 (“Asking whether the challenger has raised a substantial question of invalidity in the manner we have described may be a useful way of initially evaluating the evidence, but the ultimate question regarding the first preliminary injunction factor remains that of the patentee's likelihood of success on the merits.  The Supreme Court has stated that the general rules applicable to injunctions in civil actions apply equally to injunctions in patent cases; there is no room for making the substantial question test a substitute or replacement for the established test for injunctions.”).

             In sum, at least in comparison with precedents like Blackwelder, it is fair to see recent Supreme Court case law as raising the bar.  But PRE Holding, in my mind, does not.  And debating whether the “clear showing” language in Winter is dicta may be little more than an academic exercise.  See, e.g., DaimlerChrysler Corp. v. United States, 361 F.3d 1378, 1385 n.3 (Fed. Cir. 2004) (“even if dicta, we would feel obligated to follow the Supreme Court's explicit and carefully considered statements”) (citing prior Federal Circuit cases).